Mirum Pharmaceuticals, Inc. (MIRM)
86.01
+4.66
(+5.73%)
USD |
NASDAQ |
Oct 09, 16:00
85.90
-0.12
(-0.13%)
After-Hours: 20:00
Mirum Pharmaceuticals Cash from Investing (Quarterly) : -159.99M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -159.99M |
| March 31, 2026 | -11.57M |
| December 31, 2025 | 1.006M |
| September 30, 2025 | -2.227M |
| June 30, 2025 | -6.599M |
| March 31, 2025 | -16.13M |
| December 31, 2024 | 0.641M |
| September 30, 2024 | -18.04M |
| June 30, 2024 | -72.72M |
| March 31, 2024 | -0.013M |
| December 31, 2023 | -2.00M |
| September 30, 2023 | -182.76M |
| June 30, 2023 | 35.55M |
| March 31, 2023 | 42.02M |
| December 31, 2022 | 26.76M |
| Date | Value |
|---|---|
| September 30, 2022 | -79.53M |
| June 30, 2022 | 23.97M |
| March 31, 2022 | 36.50M |
| December 31, 2021 | 108.02M |
| September 30, 2021 | -2.237M |
| June 30, 2021 | -24.46M |
| March 31, 2021 | -32.78M |
| December 31, 2020 | -4.946M |
| September 30, 2020 | -18.91M |
| June 30, 2020 | 27.97M |
| March 31, 2020 | 33.76M |
| December 31, 2019 | -5.144M |
| September 30, 2019 | -64.19M |
| June 30, 2019 | -58.40M |
| March 31, 2019 | -0.044M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Incyte Corp. | -51.79M |
| Insmed, Inc. | 24.51M |
| Galectin Therapeutics, Inc. | 0.00 |
| Kodiak Sciences, Inc. | -0.352M |
| Praxis Precision Medicines, Inc. | 10.98M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -44.25M |
| Cash from Financing (Quarterly) | 211.44M |
| Free Cash Flow | -263.74M |
| Free Cash Flow Per Share (Quarterly) | -1.093 |
| Free Cash Flow to Equity (Quarterly) | -508.44M |
| Free Cash Flow to Firm (Quarterly) | -66.59M |
| Free Cash Flow Yield | -5.31% |